VERTEX PHARMACEUTICALS INC / MA Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price of $170.54 per share as of 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice · last filed 2026-02-13
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $170.54.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $156.36.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $151.37.
- 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $144.94.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2025-12-31 | $170.54 10-K · filed 2026-02-13 |
| 2024-12-31 | $156.36 10-K · filed 2025-02-13 |
| 2023-12-31 | $151.37 10-K · filed 2024-02-15 |
| 2022-12-31 | $144.94 10-K · filed 2023-02-10 |
| 2021-12-31 | $136.13 10-K · filed 2022-02-09 |
| 2020-12-31 | $125.83 10-K · filed 2021-02-11 |
| 2019-12-31 | $114.15 10-K · filed 2020-02-13 |
| 2018-12-31 | $93.21 10-K · filed 2019-02-13 |
| 2017-12-31 | $80.14 10-K · filed 2018-02-15 |
| 2016-12-31 | $68.92 10-K · filed 2017-02-23 |
| 2015-12-31 | $56.85 10-K · filed 2016-02-16 |
| 2014-12-31 | $45.61 10-K · filed 2015-02-13 |
| 2013-12-31 | $38.84 10-K · filed 2014-02-11 |
| 2012-12-31 | $34.54 10-K · filed 2013-03-01 |
| 2011-12-31 | $30.59 10-K · filed 2012-02-22 |
| 2010-12-31 | $28.00 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |